

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**吉林省輝南長龍生化藥業股份有限公司**

**Jilin Province Huinan Changlong Bio-pharmacy Company Limited**

*(a joint stock limited company incorporated in the People's Republic of China)*

**(Stock Code: 8049)**

**DISCLOSEABLE TRANSACTIONS  
SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS**

The Board of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the “**Company**”) is pleased to announce that on 21 August 2025, the Company subscribed for the wealth management product from Industrial and Commercial Bank of China (“**ICBC**”) in the amount of RMB50,000,000.

**IMPLICATIONS UNDER THE LISTING RULES**

As the applicable percentage ratios in respect of the ICBC subscription, on an aggregated basis pursuant to Rule 19.22 of the GEM Listing Rules, exceed 5% but are less than 25%, the ICBC subscriptions constitute discloseable transactions under Chapter 19 of the GEM Listing Rules and are therefore subject to the reporting and announcement requirements under Chapter 19 of the GEM Listing Rules, but is exempted from the compliance of the Shareholder’s approval requirement.

## The ICBC subscriptions

Further details regarding the terms of the ICBC wealth management product are as follows:

*“Ruyi Rensheng Tiantian xin hexin youxuan tongye cundan” wealth management product*

(「如意人生天天鑫核心優選同業存單」理財產品)

|                                                           |                                                                                 |
|-----------------------------------------------------------|---------------------------------------------------------------------------------|
| Date of subscription:                                     | 21 August 2025                                                                  |
| Subscription amount:                                      | RMB50,000,000                                                                   |
| Type of return:                                           | Fixed return, Non-principal guaranteed with floating return                     |
| Term of investment:                                       | No fixed term                                                                   |
| Expected annualized return rate:                          | 2%                                                                              |
| Risk level of product (internal risk rating by the bank): | Low                                                                             |
| Right of early termination or redemption:                 | ICBC is entitled to early termination of this product with 3 days’ announcement |
| Balance as at the date of this announcement:              | RMB70 million                                                                   |

On 21 August 2025, the Company purchased the ICBC wealth management and structured deposit products on an aggregated basis with a principal amount of RMB110 million. Pursuant to Rule 19.22 of the GEM Listing Rules, as at least one of the applicable percentage ratios of such purchase, when aggregated with the outstanding balance of the investment and wealth management product, exceeded 5% but was less than 25%, such aggregated purchase constituted a discloseable transaction which was subject to reporting and announcement requirements under Chapter 19 of the GEM Listing Rules.

## **INFORMATION ON THE PARTIES**

The Company is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong (長龍) and Qing Tong (清通). ICBC is a licensed bank established under the laws of the PRC, which is principally engaged in the provision of corporate and personal banking and other financial services in the PRC. To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, ICBC and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons.

## **REASONS FOR AND BENEFITS OF THE SUBSCRIPTIONS**

The subscriptions were carried out by the Company for treasury management purpose in order to maximize the utilization of its surplus cash received from its business operations, with a view to achieving balanced yields whilst maintaining high liquidity and a low level of risks. Taking into account of, among others, the low level of risks and the expected rates of return, the Company considers that the subscriptions will provide the Group with better returns than the returns on deposits generally offered by commercial banks and increase the Company's overall earnings in the long run. The Company will monitor and manage the subscriptions more closely and effectively.

As at the date of this announcement, the Company did not experience any losses on the wealth management products. Further, the subscriptions were funded by the surplus cash of the Company and are redeemable on demand or highly liquid, therefore they would not affect the working capital or the operation of the Company. As such, the Directors are of the view that the subscriptions are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

## IMPLICATIONS UNDER THE LISTING RULES

As the applicable percentage ratios in respect of the ICBC subscriptions, on an aggregated basis pursuant to Rule 19.22 of the GEM Listing Rules, exceed 5% but are less than 25%, the ICBC subscriptions constitute discloseable transactions under Chapter 19 of the GEM Listing Rules and are therefore subject to the reporting and announcement requirements under Chapter 19 of the GEM Listing Rules, but is exempted from the compliance of the Shareholder's approval requirement.

By order of the Board  
**Jilin Province Huinan Changlong Bio-pharmacy Company Limited**  
**Zhang Hong**  
*Chairman*

Tonghua, Jilin Province, the PRC

21 August 2025

*As at the date of this announcement, the Board comprises six executive directors, being Zhang Hong, Zhang Xiao Guang, Zhao Bao Gang, Wu Guo Wen, Zhang Yi and Xu Xiang Fu and three independent non-executive directors, being Gao Qi Pin, Bai Jun Gui and Tian Jie.*

*This announcement, for which the directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange for the purpose of giving information with regard to Jilin Province Huinan Changlong Bio-pharmacy Company Limited. The directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

*This announcement will remain on the "Latest Listed Company Information" page of Stock Exchange website at <http://www.hkexnews.hk> for at least 7 days from the date of its publication.*